CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Calcimedica Inc - CALC CFD

5.5768
7.77%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.6864
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.024068%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.001846%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.001
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 6.0468
Open* 5.4889
1-Year Change* 319%
Day's Range* 5.341 - 6.2951
52 wk Range 4.88-20.44
Average Volume (10 days) 13.44K
Average Volume (3 months) 74.39K
Market Cap 9.95M
P/E Ratio -100.00K
Shares Outstanding 1.57M
Revenue N/A
EPS -23.21
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date May 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 22, 2023 5.5768 0.2301 4.30% 5.3467 6.5507 5.0805
Mar 21, 2023 6.0468 1.2311 25.56% 4.8157 6.1436 4.7284
Mar 20, 2023 5.3451 -0.6469 -10.80% 5.9920 5.9920 5.0602
Mar 17, 2023 0.4280 -0.0478 -10.05% 0.4758 0.4763 0.4273
Mar 16, 2023 0.4761 -0.0195 -3.93% 0.4956 0.4958 0.4580
Mar 15, 2023 0.4937 0.0277 5.94% 0.4660 0.4969 0.4660
Mar 14, 2023 0.4762 -0.0145 -2.95% 0.4907 0.4957 0.4737
Mar 13, 2023 0.4960 -0.0093 -1.84% 0.5053 0.5151 0.4859
Mar 10, 2023 0.5041 0.0008 0.16% 0.5033 0.5120 0.4857
Mar 9, 2023 0.5346 -0.0034 -0.63% 0.5380 0.5637 0.5164
Mar 8, 2023 0.5638 0.0408 7.80% 0.5230 0.5647 0.5230
Mar 7, 2023 0.5637 0.0395 7.54% 0.5242 0.5823 0.5242
Mar 6, 2023 0.5556 -0.0273 -4.68% 0.5829 0.5829 0.5537
Mar 3, 2023 0.5476 0.0429 8.50% 0.5047 0.5588 0.5047
Mar 2, 2023 0.5345 0.0292 5.78% 0.5053 0.5347 0.5053
Mar 1, 2023 0.5390 0.0045 0.84% 0.5345 0.5832 0.5339
Feb 28, 2023 0.5285 -0.0056 -1.05% 0.5341 0.5347 0.5179
Feb 27, 2023 0.5536 -0.0004 -0.07% 0.5540 0.5543 0.5343
Feb 24, 2023 0.5439 -0.0390 -6.69% 0.5829 0.5975 0.5273
Feb 23, 2023 0.5915 0.0065 1.11% 0.5850 0.6124 0.5837

Calcimedica Inc Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018
Total revenue 0 0 0 0
Total Operating Expense 35.947 29.832 37.502 28.57
Selling/General/Admin. Expenses, Total 17.044 8.87 6.922 5.599
Research & Development 18.903 20.962 30.58 22.971
Operating Income -35.947 -29.832 -37.502 -28.57
Interest Income (Expense), Net Non-Operating 0.126 0.143 0.393 0.192
Other, Net 0 2.158 0.072 0
Net Income Before Taxes -35.821 -27.531 -37.037 -28.378
Net Income After Taxes -35.821 -27.531 -37.037 -28.378
Net Income Before Extra. Items -35.821 -27.531 -37.037 -28.378
Net Income -35.821 -27.531 -37.037 -28.378
Total Adjustments to Net Income 0 -7.189 -7.055 -4.317
Income Available to Common Excl. Extra. Items -35.821 -34.72 -44.092 -32.695
Income Available to Common Incl. Extra. Items -35.821 -34.72 -44.092 -32.695
Diluted Net Income -35.821 -34.72 -44.092 -32.695
Diluted Weighted Average Shares 21.1993 21.044 19.1556 19.1556
Diluted EPS Excluding Extraordinary Items -1.68973 -1.64988 -2.30178 -1.70681
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.68973 -1.64988 -2.30178 -1.70681
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 10.184 8.701 8.017 7.741 11.488
Selling/General/Admin. Expenses, Total 4.127 4.433 3.996 3.575 5.04
Research & Development 6.057 4.268 4.021 4.166 6.448
Operating Income -10.184 -8.701 -8.017 -7.741 -11.488
Interest Income (Expense), Net Non-Operating 0.035 0.026 0.028 0.033 0.039
Other, Net 0 0 0 0
Net Income Before Taxes -10.149 -8.675 -7.989 -7.708 -11.449
Net Income After Taxes -10.149 -8.675 -7.989 -7.708 -11.449
Net Income Before Extra. Items -10.149 -8.675 -7.989 -7.708 -11.449
Net Income -10.149 -8.675 -7.989 -7.708 -11.449
Total Adjustments to Net Income 0 0 0 0
Income Available to Common Excl. Extra. Items -10.149 -8.675 -7.989 -7.708 -11.449
Income Available to Common Incl. Extra. Items -10.149 -8.675 -7.989 -7.708 -11.449
Diluted Net Income -10.149 -8.675 -7.989 -7.708 -11.449
Diluted Weighted Average Shares 21.3578 21.3376 21.2875 21.1487 21.0204
Diluted EPS Excluding Extraordinary Items -0.47519 -0.40656 -0.37529 -0.36447 -0.54466
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.47519 -0.40656 -0.37529 -0.36447 -0.54466
  • Annual
  • Quarterly
2021 2020 2019 2018
Total Current Assets 67.078 99.24 36.271 13.445
Cash and Short Term Investments 63.67 95.033 35.956 12.834
Cash & Equivalents 13.364 33.418 15.87 12.834
Short Term Investments 50.306 61.615 20.086 0
Prepaid Expenses 2.034 4.207 0.315 0.611
Total Assets 69.088 101.794 40.66 17.813
Property/Plant/Equipment, Total - Net 1.981 1.946 1.975 1.515
Property/Plant/Equipment, Total - Gross 3.634 3.08 2.714 1.958
Accumulated Depreciation, Total -1.653 -1.134 -0.739 -0.443
Other Long Term Assets, Total 0.029 0.608 2.414 2.853
Total Current Liabilities 4.057 6.997 12.251 5.794
Accounts Payable 0.527 2.513 4.636 2.523
Accrued Expenses 2.582 3.658 4.377 2.924
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 0.948 0.826 3.238 0.347
Total Liabilities 4.065 7.008 12.251 5.794
Total Long Term Debt 0 0 0 0
Total Equity 65.023 94.786 28.409 12.019
Preferred Stock - Non Redeemable, Net 0 0 131.363 78.811
Common Stock 0.002 0.002 0 0
Additional Paid-In Capital 234.225 228.155 2.879 2.007
Retained Earnings (Accumulated Deficit) -169.188 -133.367 -105.836 -68.799
Unrealized Gain (Loss) -0.016 -0.004 0.003 0
Total Liabilities & Shareholders’ Equity 69.088 101.794 40.66 17.813
Total Common Shares Outstanding 21.3578 20.9793 19.1556 19.1556
Other Liabilities, Total 0.008 0.011
Total Preferred Shares Outstanding 0
Total Receivables, Net 0.021
Other Current Assets, Total 1.353
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 58.222 67.078 74.496 76.051 88.821
Cash and Short Term Investments 55.28 63.67 72.554 73.586 85.688
Cash & Equivalents 8.36 13.364 11.452 7.864 10.589
Short Term Investments 46.92 50.306 61.102 65.722 75.099
Prepaid Expenses 2.942 3.408 1.942 2.465 3.133
Total Assets 60.586 69.088 76.638 82.821 90.852
Property/Plant/Equipment, Total - Net 2.335 1.981 2.113 2.006 2.002
Other Long Term Assets, Total 0.029 0.029 0.029 0.136 0.029
Total Current Liabilities 4.228 4.057 4.49 4.141 6.278
Accounts Payable 0.541 0.527 2.066 2.101 1.956
Accrued Expenses 2.216 2.582 1.729 1.543 3.378
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.471 0.948 0.695 0.497 0.944
Total Liabilities 4.33 4.065 4.502 4.154 6.29
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.102 0.008 0.012 0.013 0.012
Total Equity 56.256 65.023 72.136 78.667 84.562
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 235.767 234.225 232.641 231.183 229.376
Retained Earnings (Accumulated Deficit) -179.337 -169.188 -160.513 -152.524 -144.816
Unrealized Gain (Loss) -0.176 -0.016 0.006 0.006 0
Total Liabilities & Shareholders’ Equity 60.586 69.088 76.638 82.821 90.852
Total Common Shares Outstanding 21.3578 21.3578 21.3166 21.2847 21.0559
Long Term Investments 4.628
Preferred Stock - Non Redeemable, Net 0 0
  • Annual
  • Quarterly
2021 2020 2019 2018
Net income/Starting Line -35.821 -27.531 -37.037 -28.378
Cash From Operating Activities -31.5 -32.064 -31.215 -28.216
Cash From Operating Activities 0.519 0.395 0.303 0.175
Non-Cash Items 5.433 -0.369 0.598 0.366
Changes in Working Capital -1.631 -4.559 4.921 -0.379
Cash From Investing Activities 10.751 -42.56 -20.62 -1.461
Capital Expenditures -0.488 -1.023 -0.605 -1.461
Other Investing Cash Flow Items, Total 11.239 -41.537 -20.015 0
Cash From Financing Activities 0.695 92.172 54.871 42.019
Financing Cash Flow Items 0 -4.16 -0.045 0
Issuance (Retirement) of Stock, Net 0.695 96.332 54.916 42.019
Net Change in Cash -20.054 17.548 3.036 12.342
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -10.149 -35.821 -27.146 -19.157 -11.449
Cash From Operating Activities -6.524 -31.5 -22.545 -17.045 -9.264
Cash From Operating Activities 0.122 0.519 0.383 0.247 0.118
Non-Cash Items 3.81 5.433 3.946 2.508 1.169
Changes in Working Capital -0.307 -1.631 0.272 -0.643 0.898
Cash From Investing Activities 1.52 10.751 -0.035 -9.096 -13.657
Capital Expenditures 0 -0.488 -0.484 -0.304 -0.136
Other Investing Cash Flow Items, Total 1.52 11.239 0.449 -8.792 -13.521
Cash From Financing Activities 0 0.695 0.614 0.587 0.092
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0 0.695 0.614 0.587 0.092
Net Change in Cash -5.004 -20.054 -21.966 -25.554 -22.829

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

500K+

Traders

92K+

Active clients monthly

$53M+

Monthly investing volume

$30M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Graybug Vision, Inc. Company profile

About Graybug Vision Inc

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The Company's lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD) and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Graybug Vision Inc revenues was not reported. Net loss applicable to common stockholders increased 3% to $35.8M. Higher net loss reflects Labor & Related Expenses in SGA increase from $3.3M to $7.7M (expense), Stock-based Compensation in SGA increase from $1.4M to $4.2M (expense), Fair Value Adjustments on Other Assets decrease from $2.2M (income) to $0K.

Industry: Bio Therapeutic Drugs

274 Redwood Shores Parkway
P.O. Box 144
REDWOOD CITY
CALIFORNIA 94065
US

Income Statement

  • Annual
  • Quarterly

People also watch

BTC/USD

27,590.85 Price
+0.650% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Oil - Crude

70.39 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0170%
Short position overnight fee -0.0050%
Overnight fee time 21:00 (UTC)
Spread 0.03

Gold

1,976.53 Price
+0.370% 1D Chg, %
Long position overnight fee -0.0086%
Short position overnight fee 0.0004%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

12,685.60 Price
+0.930% 1D Chg, %
Long position overnight fee -0.0241%
Short position overnight fee 0.0018%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading